Journal
JOURNAL OF IMMUNOLOGY
Volume 195, Issue 11, Pages 5117-5122Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1501657
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z01 SC006660-23, ZIA BC011337-05, ZIA BC011337-01, Z99 CA999999] Funding Source: Medline
Ask authors/readers for more resources
Cancer immunotherapy is a rapidly evolving field that exploits T cell responses to tumor-associated Ags to induce tumor rejection. Molecular identification of tumor rejection Ags has helped define several classes of Ags, including tissue differentiation and tumor germline Ags. The ability to genetically engineer Ag-specific receptors into T cells provides an opportunity to translate these findings into therapies. New immunotherapy agents, notably checkpoint inhibitors, have demonstrated unprecedented efficacy in certain cancers. However, the nature of the Ags driving those beneficial immune responses remains unclear. New evidence suggests that tumors express immunogenic, tumor-specific epitopes generated from the same mutations that drive cancer development. Correlations between cancer types responding to immunotherapies and the frequency of somatic mutations may clarify what drives natural antitumor immune responses. This fusion of tumor immunology and genetics is leading to new ways to target this class of ideal tumor-specific Ags and could allow the application of immunotherapy to many cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available